Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

This article is part of the supplement: 2006 International Meeting of The Institute of Human Virology

Open Access Poster presentation

The immunological basis of tumor therapy by targeted delivery of TNFa to tumor vessels

Enrica Balza1, Lorenzo Mortara2, Francesca Sassi1, Stefano Monteghirfo1, Barbara Carnemolla1, Patrizia Castellani1, Dario Neri3, Roberto Accollo3*, Luciano Zardi4 and Laura Borsi1

  • * Corresponding author: Roberto Accollo

Author Affiliations

1 Department of Translational Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

2 Department of Clinical and Biological Sciences, School of Medicine, University of Insubria, Varese, Italy

3 Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology, Zurich, Switzerland

4 Unit of Innovative Therapies, Istituto Giannina Gaslini, Centro Biotecnologie Avanzate, Genoa, Italy

For all author emails, please log on.

Retrovirology 2006, 3(Suppl 1):P1  doi:10.1186/1742-4690-3-S1-P1

The electronic version of this article is the complete one and can be found online at:


Published:21 December 2006

© 2006 Balza et al; licensee BioMed Central Ltd.

Poster presentation

L19mTNFa is a fusion protein constituted by the scFv L19 specific for the oncofetal ED-B domain of fibronectin and TNFa. Treatment with L19mTNFa, in combination with melphalan, induced complete tumor regression in 83% of BALB/c mice with WEHI-164 fibrosarcoma and 33% of animals with C51 colon carcinoma. All cured mice rejected challenges with the same tumor cells and, in a very high percentage of animals, also challenges with syngeneic tumor cells of different histological origin. In adoptive immunity transfer experiments the splenocytes from C51-cured mice protected 100% of naive mice both from C51 colon carcinoma and from WEHI-164 fibrosarcoma. The splenocytes from WEHI-164-cured mice protected 100% of mice from the fibrosarcoma and 80% from the C51 colon carcinoma. Similar results were also obtained in adoptive immunity transfer experiments using severely immunodepressed SCID mice. Experiments using depleted splenocytes showed that T cells play a major role in tumor rejection. These data demonstrate that the selective targeting of mTNFa to the tumor enhances its immunostimulatory properties to the point of generating a therapeutic immune response against different histologically unrelated syngeneic tumors. These findings predicate treatment approaches for cancer patients based on the targeted delivery of TNFa to tumor vasculature.